Search
Menu
Home
HTB
2024
August
August 2024
Contents
Conference reports
AIDS 2024: Ten early reports
Five days on two days off: Biktarvy in pilot FOTO study
Subcutaneous formulation of long-acting CAB/RPV discontinued
First data on third-generation integrase inhibitor from ViiV
Switching to daily oral bictegravir and lenacapavir dual therapy to simplify ART in ARTISTRY-1 study
Antiretrovirals
BMS to discontinue atazanavir/cobicistat (Evotaz) in September 2024
mpox (monkeypox)
WHO declares new mpox emergency (clade 1b): tecovirimat not effective in DRC study
HTB RSS
Early access
Lenacapavir for PrEP submitted to EMA for EU and global use
4 February 2025
New mpox vaccination sites open in the UK
3 February 2025
Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions
1 February 2025
Africa CDC special briefing on mpox and the impact of conflict
31 January 2025
All early access reports
Current issues
February 2025
January 2025
December 2024
Back issues
Special report
Impact of US elections and executive orders on global health: waiver covers PEPFAR with restrictions
1 February 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate